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BACKGROUND
Despite the routine use of prophylactic systemic antibiotics, surgical-site infection 
continues to be associated with significant morbidity and cost after colorectal sur-
gery. The gentamicin–collagen sponge, an implantable topical antibiotic agent, is 
approved for surgical implantation in 54 countries. Since 1985, more than 1 million 
patients have been treated with the sponges.
METHODS
In a phase 3 trial, we randomly assigned 602 patients undergoing open or laparo-
scopically assisted colorectal surgery at 39 U.S. sites to undergo either the insertion 
of two gentamicin–collagen sponges above the fascia at the time of surgical closure 
(the sponge group) or no intervention (the control group). All patients received 
standard care, including prophylactic systemic antibiotics. The primary end point 
was surgical-site infection occurring within 60 days after surgery, as adjudicated by 
a clinical-events classification committee that was unaware of the study-group as-
signments.
RESULTS
The incidence of surgical-site infection was higher in the sponge group (90 of 300 
patients [30.0%]) than in the control group (63 of 302 patients [20.9%], P = 0.01). 
Superficial surgical-site infection occurred in 20.3% of patients in the sponge group 
and 13.6% of patients in the control group (P = 0.03), and deep surgical-site infec-
tion in 8.3% and 6.0% (P = 0.26), respectively. Patients in the sponge group were 
more likely to visit an emergency room or surgeon’s office owing to a wound-related 
sign or symptom (19.7%, vs. 11.0% in the control group; P = 0.004) and to be re-
hospitalized for surgical-site infection (7.0% vs. 4.3%, P = 0.15). The frequency of 
adverse events did not differ significantly between the two groups.
CONCLUSIONS
Our large, multicenter trial shows that the gentamicin–collagen sponge is not ef-
fective at preventing surgical-site infection in patients who undergo colorectal sur-
gery; paradoxically, it appears to result in significantly more surgical-site infections. 
(Funded by Innocoll Technologies; ClinicalTrials.gov number, NCT00600925.)
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Postoperative surgical-site infection continues to be a significant problem after general surgical procedures, especially co-
lorectal surgery. Reported incidences of surgical-
site infection among patients who undergo co-
lorectal surgery range from 8.2%1 to 26%,2 with 
an incidence of approximately 18 to 20% in most 
series.3-7 Postoperative surgical-site infection is 
associated with a significant rate of complica-
tions and cost.8-10 Thus, prevention of these fre-
quent infections has been the focus of numerous 
strategies.2-7,11
The gentamicin–collagen sponge was devel-
oped to prevent and treat wound infections by 
providing high gentamicin concentrations lo-
cally, avoiding the high systemic concentrations 
associated with nephrotoxicity. The sponge’s col-
lagen matrix biodegrades and disappears within 
days to weeks. Pharmacokinetic data show that 
implantation of one to five sponges (correspond-
ing to a gentamicin dose of 130 to 650 mg) re-
sulted in local-tissue gentamicin concentrations 
of 170 to 9000 μg per milliliter. These concen-
trations exceed the minimum inhibitory concen-
trations for many microorganisms. Systemic con-
centrations of gentamicin, however, remained 
below 2 μg per milliliter 24 hours after implan-
tation.12
The sponge received marketing approval in 
Germany in 1985 and is currently approved for 
use in another 53 countries. Since 1985, more 
than 2 million sponges manufactured by Innocoll 
Technologies (Gallowston, Ireland) have been 
used to treat more than 1 million patients across 
a broad range of clinical indications. Several 
studies suggest that the sponge may be effective 
in the prevention and treatment of infections 
after general surgery.6,13,14 In a single-center, 
randomized trial, patients who underwent colo-
rectal surgery and received a sponge had a 70% 
decrease in surgical-site infection, as compared 
with those who did not receive a sponge.6 The 
current phase 3 trial was designed to confirm 
these promising data and support regulatory ap-
proval in the United States.
Me thods
study oversight
Patients were enrolled at 39 sites in the United 
States. The study was coordinated by the Duke 
Clinical Research Institute (DCRI). The DCRI–
Duke University coauthors wrote the study proto-
col, gathered and analyzed the data, vouch for the 
accuracy and integrity of the data and analysis, 
and wrote the manuscript. Institutional review 
boards at participating institutions approved the 
study protocol, and the study was performed in 
accordance with it.
Patients
All patients provided written informed consent. 
A complete list of inclusion and exclusion crite-
ria, along with a detailed list of the surgical pro-
cedures, is provided in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org. Inclusion criteria were an age of 18 
years or older and having 1 of 13 types of colo-
rectal surgery scheduled. Laparoscopically as-
sisted procedures requiring an incision of at least 
7 cm were allowed, a length that is consistent 
with the use of a laparotomy “hand port” in many 
so-called laparoscopic colorectal procedures. Ex-
clusion criteria included the presence of a clini-
cally significant concomitant surgical procedure, 
use of a laparoscopic or other minimally invasive 
surgical approach involving a laparotomy inci-
sion shorter than 7 cm, laparotomy within the 
60-day period before the screening visit or a 
planned second laparotomy within the 60-day 
period after surgery, and a situation in which it 
was technically impossible to insert two sponges 
above the fascia.
Study Procedure
Study Treatment and Randomization
Each sponge (10 by 10 cm) contained 280 mg of 
collagen and 130 mg of gentamicin. In patients 
who were randomly assigned to receive a sponge, 
two sponges were inserted anteriorly to the fas-
cia, along the full length of the incision, imme-
diately before closure of the surgical wound. To 
facilitate placement in the wound, the sponges 
could be cut into strips while dry. No sponges 
were placed in control patients. Patients in the 
sponge group in whom reexploration of the sur-
gical site was necessary within 1 week after the 
first surgery had two new sponges inserted at the 
time of closure. All participating surgeons un-
derwent a training and certification process that 
included the viewing of a video outlining proper 
use of the study sponge.
Randomization occurred after the surgical 
incision had been made, with the use of a cen-
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tral randomization system. Control patients did 
not receive a placebo sponge (a sponge contain-
ing collagen but not gentamicin), since bacteria 
might have grown on a sponge that did not con-
tain the antibiotic. Therefore, surgeons could 
not be unaware of the study-group assignments, 
but patients and members of the adjudication 
committee did remain unaware.
Administration of Antibiotics and Bowel 
Preparation
In accordance with published guidelines,15 the 
protocol called for initiation of one of the follow-
ing antibiotic regimens within 60 minutes before 
incision: cefazolin plus metronidazole, cefoxitin, 
or ciprofloxacin plus clindamycin or metronida-
zole. Dosing was based on body weight, and the 
drugs were not to be continued for more than 24 
hours after surgery. Preoperative oral antibiotics 
were not required but could be added to the sys-
temic antibiotic prophylaxis: oral neomycin plus 
oral erythromycin or oral neomycin plus oral 
metronidazole.15 The use of topical antibiotics, 
other than the gentamicin in the sponge, was 
prohibited in patients randomly assigned to re-
ceive the sponge. At least one of the following 
bowel-preparation regimens was required: use of 
a laxative (polyethylene glycol, sodium phosphate, 
or a magnesium citrate–based regimen) or a high-
volume enema.
Data Collection
Standard preoperative demographic and intraop-
erative characteristics were recorded, and we also 
collected data on variables suspected to play a 
role in surgical-site infection. The risk of infec-
tion was assessed with the use of the National 
Nosocomial Infection Surveillance System.4,16
Primary and Secondary End Points
The primary study end point was surgical-site in-
fection within the laparotomy wound during the 
period from surgery through postoperative day 60. 
Key secondary efficacy end points included the in-
cidence of deep surgical-site infections, superficial 
surgical-site infections, surgically treated surgical-
site infections (defined as infection treated with 
any type of surgical intervention, including open-
ing of the wound), postoperative hospital length 
of stay, and ASEPSIS score through 60 days after 
colorectal surgery.4,17,18 The validated ASEPSIS 
score assigns points for nine variables related to 
infection, including use of antibiotics, drainage of 
pus under local anesthesia, wound débridement 
under general anesthesia, isolation of bacteria, 
prolonged postoperative hospitalization, and find-
ings on daily examination of the wound.4,17,18 The 
minimum score is 0, and there is no theoretical 
maximum score; higher scores indicate a worse 
infection. We assessed the change in the serum 
creatinine level from baseline, reporting the peak 
level during the first 7-day postoperative period or 
the period until hospital discharge if discharge 
occurred before day 7. Patients assessed their pain 
and wound healing according to a structured 
questionnaire administered 30 and 60 days after 
surgery. Data were recorded for death from any 
cause at 60 days, visits to the emergency depart-
ment or surgical office in association with wound-
related signs or symptoms, rehospitalization for 
surgical-site infection, and serum gentamicin lev-
els at several sites. Blood samples were obtained at 
baseline (after incision) and then at 2±0.5, 6±0.5, 
12±1, 24±2, and 48±2 hours after surgical-wound 
closure for the determination of serum gentami-
cin levels.
Clinical Events Committee
The independent clinical events committee con-
sisted of three independent infectious disease ex-
perts who were unaware of the study-group as-
signments. All suspected wound-infection events 
were reviewed independently by two of the three 
experts. Cases for which the two experts dis-
agreed were reviewed by the third expert. Possi-
ble wound infections were identified by events 
including signs of infection, administration of 
postoperative antibiotics, rehospitalization, and 
death. After review of blinded medical rec-
ords,4,17,18 the committee ascertained the pres-
ence or absence, extent, and severity of all infec-
tions according to standardized criteria, including 
those from the Centers for Disease Control and 
Prevention4,16,17,19 and Itani and colleagues2: super-
ficial infections that involved the skin and super-
ficial fat but did not threaten the fascia, deep 
infections involving deeper soft tissue of the inci-
sion and potentially threatening the fascia, and 
organ-space infections below the fascia (which 
are usually manifested as abscess). Data for in-
fections not considered to be related to laparotomy 
(e.g., perineal-incision infection, peristomal in-
fection, infection at the intravenous catheter site, 
or pneumonia) were not included in the analysis.
The New England Journal of Medicine 
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Statistical Analysis
All analyses were performed by the statistical 
team at the DCRI. Calculations during the plan-
ning phase indicated that enrollment of 592 pa-
tients (296 per study group) would be required to 
detect a 50% relative reduction in the incidence 
of surgical-site infection in the sponge group as 
compared with the control group, with a power of 
at least 85% and a two-sided type I error rate of 
0.05. On the basis of previous trials, we assumed 
a 16% incidence of surgical-site infection.
The primary analysis was based on intention-
to-treat methods. We also performed a per-proto-
col analysis, as a prespecified secondary analy-
sis, which included all patients who completed 
the study and had no major deviations from the 
prespecified protocol. We compared the primary 
end point between the two study groups by means 
of a two-sided chi-square test involving data 
across all sites, after checking the treatment-by-
site interaction. In all secondary efficacy and sub-
group analyses, a nominal two-sided P value of 
less than 0.05 was considered to indicate statis-
tical significance, and the results were consid-
ered to be descriptive.
Descriptive statistical comparisons between 
the two study groups were performed with the 
use of chi-square tests or Fisher’s exact test, as 
appropriate, for categorical secondary efficacy 
end points and with the use of analysis-of-vari-
ance techniques or Wilcoxon rank-sum tests, as 
appropriate, for continuous secondary efficacy 
end points. The log-rank tests were used to com-
pare the time to first surgical-site infection be-
tween two study groups. Kaplan–Meier survival 
estimates of the time to first surgical-site infec-
tion were also calculated.
No formal interim analysis was planned. An 
independent data and safety monitoring com-
mittee monitored the trial on an ongoing basis. 
602 Underwent randomization
674 Patients were enrolled
72 Were excluded
54 Had a planned change in surgery or no 
longer met eligibility criteria
7 Withdrew consent
6 Were enrolled but not studied because
trial sample size was reached
4 Had an unknown reason
1 Was withdrawn by investigator
300 Were assigned to receive gentamicin–
collagen sponges
281 Received 2 sponges
15 Received only 1 sponge
4 Did not receive a sponge
302 Were assigned not to receive
sponges (control)
302 Received assigned intervention
3 Were lost to follow-up
5 Were lost to follow-up
300 Had data included in the intention-
to-treat analysis
26 Were excluded from the per-
protocol analysis
7 Did not meet eligibility criteria
15 Received only 1 sponge
4 Did not receive a sponge
302 Had data included in the intention-
to-treat analysis
10 Were excluded from the per-
protocol analysis because
eligibility criteria were not met
Figure 1. Enrollment, Randomization, and Follow-up of the Patients, According to Study Group.
The New England Journal of Medicine 
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All statistical analyses were performed with the 
use of SAS software (version 9.2).
R esult s
Overall, 602 patients were enrolled at 39 U.S. 
sites between February 2008 and March 2009 
(Fig. 1). Of the 300 patients randomly assigned to 
receive two sponges, 281 (93.7%), 15 (5.0%), and 
4 (1.3%) received two, one, and no sponges, re-
spectively. A total of 8 of the 602 patients (1.3%; 
3 in the sponge group and 5 in the control group) 
were lost to follow-up at day 60.
Patients in both groups underwent bowel re-
section primarily for colon or rectal carcinoma 
(in 307 of 602 patients [51.0%]) or diverticulitis 
or inflammatory bowel disease (217 of 602 pa-
tients [36.0%]). The study groups were balanced 
with regard to baseline characteristics (Table 1) 
as well as surgical preparation and intraopera-
tive characteristics (Table 2). Laparoscopically 
assisted surgery that was not converted to an 
open procedure was performed in 51 of the 300 
patients (17.0%) in the sponge group and 58 of 
the 302 patients (19.2%) in the control group. 
Adjudicated surgical-site infection was more 
likely to occur in association with open surgery 
(139 of 493 patients [28.2%]) than with laparo-
Table 1. Baseline Characteristics of the Patients, According to Study Group.*
Characteristic
Gentamicin–Collagen 






White race — no. (%)† 272 (90.7) 273 (90.4)







Waist circumference — cm
Median 96.0 96.5
IQR 86.0–106.7 86.4–106.7
Male sex — no. (%) 181 (60.3) 158 (52.3)
Hypertension — no. (%) 140 (46.7) 122 (40.4)
Diabetes — no. (%) 37 (12.3) 47 (15.6)
Smoking status — no. (%)
Current or previous 142 (47.3) 147 (48.7)
Current 47 (15.7) 46 (15.2)
Chronic obstructive pulmonary disease — no. (%) 17 (5.7) 12 (4.0)
Peripheral vascular disease — no. (%) 12 (4.0) 13 (4.3)
Previous laparotomy — no./total no. (%) 131/300 (43.7) 124/301 (41.2)
Previous radiation to abdomen — no. (%) 42 (14.0) 45 (14.9)
Chemotherapy within 6 wk before surgery — no. (%) 22 (7.3) 17 (5.6)
Corticosteroid use within 1 mo before surgery — no. (%) 25 (8.3) 17 (5.6)
History of abdominal fistula — no. (%) 10 (3.3) 10 (3.3)
Renal insufficiency — no. (%)¶ 5 (1.7) 5 (1.7)
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scopically assisted surgery (14 of 109 patients 
[12.8%]).
In the primary analysis, surgical-site infec-
tions occurred more frequently in the sponge 
group (90 of 300 patients [30.0%]) than in the 
control group (63 of 302 [20.9%]) (P = 0.01) (Ta-
ble 3). The incidence of superficial surgical-site 
infection was 20.3% in the sponge group, versus 
13.6% in the control group, and the incidence of 
deep surgical-site infections was 8.3% versus 
6.0%. Patients in the sponge group were more 








Serum albumin — g/dl
Median 4.0 4.0
IQR 3.6–4.3 3.7–4.4
Serum glucose — mg/dl
Median 99 96
IQR 89–111 89–109






Serum creatinine — mg/dl
Median 0.9 0.9
IQR 0.8–1.1 0.8–1.0
Preoperative core temperature — °C
Median 97.7 97.7
IQR 97.0–98.2 97.0–98.2
Preoperative hospital stay — days
Median 0.0 0.0
IQR 0.0–0.0 0.0–0.0
NNISS score — no. (%)‖
0 32 (10.7) 38 (12.6)
1 166 (55.3) 159 (52.6)
2 102 (34.0) 105 (34.8)
3 0 0
* To convert the values for glucose to millimoles per liter, multiply by 0.05551. To convert the values for creatinine to 
 micromoles per liter, multiply by 88.4. IQR denotes interquartile range.
† Race was self-reported.
‡ The American Society of Anesthesiologists physical status classification score can range from 0 to 6, with higher scores 
representing a worse condition. A score of 3 or 4 represents severe systemic disease.
§ The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶ Renal insufficiency was defined as a preoperative serum creatinine level of 2.5 mg per deciliter (221 μmol per liter) or 
more.
‖ The National Nosocomial Infection Surveillance System (NNISS) score can range from 0 to 3 points, with a higher 
score representing a higher risk of infection. One point is awarded for an American Society of Anesthesiologists physi-
cal status classification score of 3 or more, one point is awarded for a contaminated or nonsterile operation, and one 
point is awarded for a duration of surgery of more than 2 hours.
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Table 2. Characteristics of Surgical Preparation and Procedure, According to Study Group.*
Characteristic
Gentamicin–Collagen 
Sponge (N = 300)
Control  
(N = 302)
Oral antibiotics administered preoperatively — no. (%) 44 (14.7) 38 (12.6)
Preoperative bowel preparation — no. (%)
Laxative use and complete bowel preparation 273 (91.0) 277 (91.7)
Enema 4 (1.3) 5 (1.7)
Other 9 (3.0) 12 (4.0)
None 17 (5.7) 16 (5.3)
Preoperative shower with chlorhexidine soap — no. (%) 39 (13.0) 44 (14.6)
Hair at operative site not removed — no./total no. (%) 61/299 (20.4) 82/302 (27.2)
Preincision skin preparation — no. (%)
With povidone–iodine 220 (73.3) 220 (72.8)
With alcohol 42 (14.0) 42 (13.9)
With chlorhexidine-based agent 110 (36.7) 117 (38.7)
IV antibiotics administered within 60 min before incision 284 (94.7) 289 (95.7)
Antibiotic administered before incision — no. (%)
Aztreonam 0 1 (0.3)
Cefotetan 4 (1.3) 2 (0.7)
Cefazolin 89 (29.7) 92 (30.5)
Cefoxitin 111 (37.0) 105 (34.8)
Clindamycin 6 (2.0) 6 (2.0)
Ciprofloxacin 83 (27.7) 88 (29.1)
Metronidazole 173 (57.7) 182 (60.3)
Other 6 (2.0) 8 (2.6)
Prophylactic IV antibiotics discontinued within 24 hr after incision —  
no./total no. (%)
262/296 (88.5) 267/301 (88.7)
Surgical procedure performed — no. (%)
Left hemicolectomy 17 (5.7) 21 (7.0)
Transverse colectomy 12 (4.0) 11 (3.6)
Segmental (sleeve) left colon resection 1 (0.3) 6 (2.0)
Total abdominal colectomy with ileorectal anastomosis 12 (4.0) 14 (4.6)
Total abdominal colectomy with ileostomy 18 (6.0) 15 (5.0)
Total abdominal proctocolectomy 23 (7.7) 15 (5.0)
Low anterior resection 77 (25.7) 105 (34.8)
Sigmoid resection 65 (21.7) 60 (19.9)
Nonemergency Hartman’s procedure 7 (2.3) 4 (1.3)
Colotomy with polypectomy distal to hepatic flexure 0 1 (0.3)
Colostomy takedown through laparotomy incision 21 (7.0) 15 (5.0)
Ileal pouch anal anastomosis with or without stoma 40 (13.3) 29 (9.6)
Abdominal–perineal resection of the rectum 22 (7.3) 16 (5.3)
Other 7 (2.3) 11 (3.6)
Laparoscopically assisted surgery† 51 (17.0) 58 (19.2)
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Sponge (N = 300)
Control  
(N = 302)
Laparotomy incision length — cm
Median 16.0 14.0
IQR 9.3–23.0 9.0–20.0
Method to close laparotomy incision — no. (%)
Staples 239 (79.7) 219 (72.5)
Sutures 68 (22.7) 88 (29.1)
Glue 3 (1.0) 5 (1.7)
Duration of surgery — hr
Median 2.8 2.9
IQR 2.1–4.0 2.2–3.7
Abdominal surgical drain inserted — no. (%) 111 (37.0) 113 (37.4)
Crystalloid volume administered intraoperatively — liters
Median 3.0 3.0
IQR 2.3–4.0 2.4–4.0
Colloid volume administered intraoperatively — liters
Median 0.0 0.0
IQR 0.0–0.5 0.0–0.5
Nitrous oxide used — no. (%) 33 (11.0) 18 (6.0)







Administered any dexamethasone in perioperative period — no. (%) 31 (10.3) 41 (13.6)
Peak serum glucose in first 24 hr after surgery — mg/dl
Median 140 142
IQR 119–167 116–173
Perioperative allogeneic red-cell transfusion — no. (%) 48 (16.0) 56 (18.5)
Core temperature at end of surgery — °C
Median 36.5 36.4
IQR 36.2–36.8 36.2–36.8
Core temperature at end of surgery ≥36°C — no./total no. (%) 264/297 (88.9) 250/297 (84.2)
* To convert the values for glucose to millimoles per liter, multiply by 0.05551. FiO2 denotes fraction of inspired oxygen, 
IQR interquartile range, and IV intravenous.
† Laparoscopically assisted surgery did not include procedures in which the laparoscopic approach was abandoned  
(i.e., conversion to open laparotomy).
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emergency department or surgical office with a 
wound-related sign or symptom (19.7 vs. 11.0%, 
P = 0.004); rehospitalization for surgical-site in-
fection occurred in 7.0% of patients in the sponge 
group and 4.3% of patients in the control group 
(P = 0.15). Times to surgical-site infection are 
shown in Figure 2.
The frequency of adjudicated surgical-site in-
fection was 44.7% (134 of 300 patients) in the 
sponge group, versus 34.4% (104 of 302 patients) 
in the control group, as assessed by the site in-
vestigators (which is similar to results on the basis 
of assessment by the clinical events committee). 
Analyses performed in the per-protocol population 
of 566 patients yielded results similar to those 
for the intention-to-treat population (Table 3).
Among patients in the per-protocol popula-
tion with adjudicated surgical-site infection, po-
tential pathogens were isolated in samples from 
44 patients in the sponge group and 28 patients 
in the control group (Table 1 in the Supplemen-
tary Appendix). The organisms found to be most 
frequently resistant to gentamicin include Entero-
coccus faecalis (in 3 of 9 isolates), Enterococcus faecium 
(1 of 3 isolates), Escherichia coli (1 of 9 isolates), 
Proteus mirabilis (1 of 5 isolates), and Staphylococcus 
epidermidis (9 of 12 isolates) (Table 2 in the Sup-
plementary Appendix). All but 2 of the 15 resis-
tant isolates were cultured from patients in the 
sponge group.
Peak serum gentamicin levels ranged from 
0.9 to 4.7 μg per milliliter (mean, 2.4) and de-
creased to a mean (±SD) of 0.4±0.4 μg per mil-
liliter by 48 hours after sponge insertion (Fig. 1 
in the Supplementary Appendix). The mean per-
cent increase from baseline in the peak serum 
creatinine level was similar in the two groups 
(14.8±42.6% in the sponge group and 15.4±45.1% 
in the control group).
Eighteen patients required reexploration of 
the surgical wound: 11 patients in the sponge 
group and 7 patients in the control group. Exclu-
sion of data from these patients from the primary 
analysis did not change the overall results (with 
a rate of adjudicated surgical-site infection of 
29.4% in the sponge group vs. 21.4% in the con-
trol group, P = 0.03). Six patients had died by day 
60 (1 patient in the sponge group and 5 patients 
in the control group). No significant differences 
were found between the two groups regarding 
serious adverse events (Table 3 in the Supple-
mentary Appendix).
Given the increase in surgical-site infection 
observed with the gentamicin–collagen sponge, 
a post hoc analysis was performed to investigate 
a possible mechanism for this effect. We specu-
lated that the presence of sponge mass (assum-
ing two sponges were placed) may have been a 
mechanical barrier to early wound healing that 
promoted infection. However, no clear associa-
tion was seen between surgical-site infection and 
incision length, waist circumference, or body-
mass index according to study group (results not 
shown). In addition, there was no overt differ-
ence in the degree of wound healing between 
the two groups at 30 or 60 days, on the basis 
of data from a structured patient questionnaire 
(Table 4 in the Supplementary Appendix).
Discussion
The gentamicin–collagen sponge, developed to 
deliver a high local and wound concentration of 
gentamicin, has undergone testing throughout 
northern Europe. For example, a single-center, 
nonblinded study involving 221 patients under-
going colorectal surgery showed a 70% relative 
reduction of the incidence of surgical-site infec-
tion with the use of the sponge (18.4%, vs. 5.6% 
with no sponge; P<0.01).6 These results served as 
strong preliminary data for our trial. However, 
the results of our large, randomized clinical trial 
showed that use of the sponge, as compared with 
no sponge, did not reduce the incidence of surgi-
cal-site infection in patients undergoing colo-
rectal surgery. Contrary to initial expectations, 
patients randomly assigned to undergo sponge 
placement, as compared with those who did not 
undergo sponge placement, had a higher inci-
dence of surgical-site infection, were more likely 
to visit an emergency room or surgical office for 
a wound-related sign or symptom, and more fre-
quently underwent rehospitalization for surgical-
site infection. These results raise important new 
questions about the best method for reducing the 
risk of this important complication, which still 
affects about one in five patients undergoing colo-
rectal surgery, despite skin decontamination 
and administration of systemic antibiotics.3-7
Our data do not allow us to identify with 
certainty the cause of the lack of efficacy we 
observed. However, we can speculate that sev-
eral factors may have been operational. First, 
though the microorganisms cultured from in-
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Sponge (N = 300)
Control  
(N = 302) P Value
Intention-to-treat analysis
SSI — no. of patients (%)
Any (primary end point) 90 (30.0) 63 (20.9) 0.01
Surgically treated 71 (23.7) 49 (16.2) 0.02
Superficial 61 (20.3) 41 (13.6) 0.03
Deep 25 (8.3) 18 (6.0) 0.26




Rehospitalization for SSI — no. of patients (%) 21 (7.0) 13 (4.3) 0.15
Visit to ER or physician for wound-related sign or symptom 
— no. of patients/total no. (%)
57 (19.7) 31 (11.0) 0.004








SSI — no. of patients (%)
Any (primary end point) 83 (30.3) 62 (21.2) 0.01
Surgically treated 68 (24.8) 48 (16.4) 0.01
Superficial 56 (20.4) 41 (14.0) 0.04
Deep 23 (8.4) 18 (6.2) 0.31




Rehospitalization for SSI — no. of patients (%) 20 (7.3) 12 (4.1) 0.10
Visit to ER or physician for wound-related sign or symptom 
— no. of patients/total no. (%)
53/265 (20.0) 30/272 (11.0) 0.004
Postoperative hospital length of stay — days 0.48
Median 6.0 6.0
IQR 5.0–8.0 4.0–8.0
* ER denotes emergency room, and IQR interquartile range.
† The ASEPSIS score reflects nine variables related to the infection, including use of antibiotics, drainage of pus under lo-
cal anesthesia, wound débridement under general anesthesia, isolation of bacteria, prolonged postoperative hospital-
ization, and findings on daily examination of the wound. The minimum score is 0, and there is no theoretical maximum 
score; higher scores indicate a worse infection. The mean (±SD) score was 6.1±10.4 in the sponge group and 5.2±11.0 
in the control group in the intention-to-treat population and 6.0±10.2 and 5.3±11.1, respectively, in the per-protocol 
population.
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fected surgical wounds were similar in distribu-
tion between the two study groups (Table 1 in 
the Supplementary Appendix), cultures from the 
sponge group contained significantly more re-
sistant bacteria than cultures from the control 
group. These findings may be partly explained 
by the results of the time-kill testing (which 
measures the antimicrobial activity of a drug) 
independently performed by the sponsor with 
doses of 100 μg and 300 μg of gentamicin sul-
fate per milliliter (Prior D: personal communica-
tion). Regrowth of S. aureus, coagulase-negative 
staphylococci, and enterococcus was found at 24 
hours. These results are consistent with the con-
clusion by Tam and colleagues20 that gentamicin 
should be administered every 8 hours to elimi-
nate staphylococci and enterococci, in contrast to 
administration every 24 hours, which is effective 
against gram-negative bacilli. Second, gentami-
cin may elute too rapidly to increase the efficacy 
of systemic preoperative antibiotics. In support 
of this hypothesis are data showing low wound 
and local levels of gentamicin 12 hours after 
sponge insertion.21 We found what appeared to 
be a transient early benefit of the sponge (Fig. 2), 
with a subsequent reversal in that effect, which 
may be consistent with the failure of the sponge 
to provide a sustained local level of gentamicin. 
A sponge with depleted antibiotic levels could 
harbor bacteria and thereby increase the risk of 
infection. Third, the collagen used to construct 
the sponges we used could have stimulated a 
deleterious local effect. An additional possibility 
is that the collagen may have been a mechanical 
barrier to rapid and effective closure of the 
wound, thus providing additional time for bacte-
rial penetration to occur. Arguing against this 
hypothesis is the fact that our post hoc analyses 
showed no clear association between treatment 
effect and wound length or surrogates for wound 
depth (waist circumference and body-mass index).
If the sponge is not effective, why did results 
of an earlier study by Rutten and Nijhuis6 sug-
gest such a strong treatment benefit? In the 
previous study, the duration of follow-up was not 
reported; duration could be a factor, since evi-
dence of harm became apparent in our study 
only 3 weeks after surgery. In addition, the pre-
vious study used a lower dose of gentamicin (one 
sponge containing 130 mg of gentamicin) than 
was used in our study (two sponges, each con-
taining 130 mg of gentamicin). However, it is 
unclear why our use of a higher dose of gen-
tamicin would yield such different results, un-
less harm was mediated by a mechanical effect 
of the sponge. An important difference between 
the study by Rutten and Nijhuis and ours is that 
they did not use several quality-control measures 
(e.g., verification of data from on-site monitor-
ing and source documents, central adjudication 
of end points by an independent committee that 
was unaware of the group assignments, and the 
inclusion of a large number of surgical sites [1, vs. 
39 in our study] and patients). The discrepancy 
in results may be related to the fact that findings 
from positive single-center trials are often not 
confirmed in larger multicenter trials.22 Further-
more, differences among races and ethnic groups 
and among regions may have resulted in the dif-
ferent results between our U.S.-based trial and 
previous studies.23
A limitation of our trial is that it was de-
signed to study the prevention of infection, so its 
results cannot be used to address whether the 
sponge is effective for the treatment of infec-
tion.13 Another limitation of our trial is that it 
did not address the efficacy of sponge placement 
below the fascia.
In conclusion, our large, multicenter trial 
shows that the gentamicin–collagen sponge is 




















Figure 2. Kaplan–Meier Estimates of the Number of Days from Surgery 
to Surgical-Site Infection (SSI) within the 60-Day Postoperative Period,  
According to Study Group.
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in patients undergoing colorectal surgery and, 
as compared with the placement of no sponges, 
appears to result in significantly more surgical-
site infections.
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